Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $416.81, demonstrating a +2.01% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.53%. Meanwhile, the Dow gained 0.52%, and the Nasdaq, a tech-heavy index, added 0.52%. Coming into today, shares of the drugmaker had gained 5.55% in the past month. In that same time, the Medical sector gained 2.87%, while the S&P 500 gained 0.71%. Analysts and investors alike will be keeping a close eye on the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to go public on November 3, 2025. In that report, analysts expect Vertex Pharmaceuticals to post earnings of $4.53 per share. This would mark year-over-year growth of 3.42%. At the same time, our most recent consensus estimate is projecting a revenue of $3.04 billion, reflecting a 9.73% rise from the equivalent quarter last year. For the full year, the Zacks Consensus Estimates project earnings of $17.95 per share and a revenue of $11.98 billion, demonstrating changes of +4173.81% and +8.76%, respectively, from the preceding year. It's also important for investors to be aware of any recent modifications to analyst estimates for Vertex Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.3% lower. Vertex Pharmaceuticals is currently sporting a Zacks Rank of #3 (Hold). With respect to valuation, Vertex Pharmaceuticals is currently being traded at a Forward P/E ratio of 22.77. This denotes a premium relative to the industry average Forward P/E of 20.11. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 34% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks